| External factors: | C-1311 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Lung cancer |
| Experiment: | Cell morphological analysis//SA-β-gal activity assay//Flow cytometry |
| Description: | Cells were treated with C-1311 and stained for SA-β-gal, a marker of senescence. In A549 cells, increased SAβ-gal staining was visible within 48 hours of treatment. After 8 days of continuous drug exposure, more than 80% of the cells displayed SA-β-gal activity and flattened and enlarged morphology that was consistent with senescence phenotype. Although H460 cells also stained positively for SA-β-gal, the percentage of cells undergoing senescence was 2-fold lower than in A549 cells.In contrast, C-1311 exposure led to the substantial accumulation in the G1 phase in H460 cells,although G2-M arrest was also evident. |
| Target gene: | BECLIN1//ATG5 |
| R-EF-Target gene: | --//-- |
| Official symbol(s): | BECLIN1//ATG5 |
| Target gene experiment: | -- |
| Target gene description: | SAβ-gal staining indicated that knockdown of Beclin 1 significantly attenuated C-1311–induced senescence in A549 cells.After 144 hours of C-1311 exposure, downregulation of ATG5 in A549 cells resulted in an approximately 25% inhibition of senescence compared with ATG5-positive cells. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: